What Are the Treatments for ARSACS Muscle Spasticity?
At a Glance
ARSACS muscle spasticity is managed using oral medications like baclofen and gabapentin, targeted Botox injections, and physical therapy. The primary goal is finding a careful balance: relieving painful stiffness without eliminating the functional muscle tone needed to stand and walk.
In this answer
4 sections
Currently, there is no cure for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), so treatment for muscle spasticity focuses on managing symptoms to maximize your comfort and quality of life [1][2]. For severe muscle stiffness and spasms, the standard of care includes oral medications like baclofen to reduce tightness, gabapentin for nerve pain and cramps, and localized botulinum toxin (Botox) injections for specific problem areas [3][4][5]. However, treating ARSACS requires a careful “balancing act”—doctors must relieve painful stiffness without taking away the muscle tone that helps you stand and walk [6].
Oral Medications: Baclofen, Gabapentin, and Alternatives
For many patients, oral medications are the first step in managing muscle stiffness and cramps.
- Baclofen: This widely used muscle relaxant works in the spinal cord to decrease muscle spasms and tightness [3][7]. Because the dose must be increased very slowly, it can take several weeks or months to find the right amount. High doses can cause side effects like sedation, fatigue, and muscle weakness (a decrease in muscle strength) [8]. It is critical that you never stop taking baclofen abruptly, as this can trigger a severe withdrawal syndrome [9][10].
- Gabapentin: ARSACS can cause painful muscle cramps and neuropathic pain (shooting or burning pain caused by nerve damage) [4]. Gabapentin calms overactive nerves and is often used to manage these painful symptoms [11]. Important warning: Gabapentin can commonly cause dizziness and sleepiness, which may temporarily worsen your ataxia and increase your risk of falling.
- Other Options: If baclofen or gabapentin are not well-tolerated, your doctor may suggest other oral muscle relaxants, such as tizanidine, to help find the right balance for your body.
Targeted Relief: Botulinum Toxin Injections
Because oral medications circulate through your entire body, they can sometimes cause too much overall weakness. When spasticity is severe in just a few specific areas, botulinum neurotoxin type A (BoNT-A)—commonly known as Botox—can be an excellent alternative [5].
Botox is injected directly into the tightest, most problematic muscles to block the nerve signals causing the spasm [12]. This provides localized relief without making the rest of your body feel weak or tired. However, Botox is not a permanent fix; the effects typically wear off, requiring repeat injections every 3 to 4 months. Side effects are usually minor but can include localized pain at the injection site or temporary, excessive weakness in the injected muscle.
The Clinical Balancing Act: Spasticity vs. Weakness
The most critical conversation you will have with your neurologist involves the trade-off between treating spasticity and maintaining your mobility.
While muscle stiffness is uncomfortable, it often acts as a natural brace. In ARSACS, patients have underlying muscle weakness and poor coordination (ataxia). The spasticity provides a “functional tone” that makes the legs rigid enough to support the body’s weight [6][13].
If anti-spasticity medications are given at too high a dose, they strip away this functional tone. Your legs may become too relaxed and weak, which can cause your knees to buckle, significantly worsen your ataxia, and increase your risk of falling [6]. Therefore, the goal of medication is not to eliminate spasticity entirely, but to reduce it just enough to improve comfort and flexibility without compromising your ability to stand and walk.
Combining Treatments with Physical Therapy
Medications are rarely enough on their own. The most effective approach pairs pharmacological treatments with specialized physical therapy. Regular stretching and strengthening exercises help maintain joint flexibility. Additionally, mobility training—such as training for the safe use of walking aids, and manual wheelchair skills training for those who use wheelchairs—ensures you can safely navigate your environment and maintain your independence [14][15].
Common questions in this guide
Why shouldn't I stop taking baclofen suddenly?
Can gabapentin make my ARSACS ataxia worse?
Why might my doctor recommend Botox instead of oral muscle relaxants?
Why doesn't my doctor want to get rid of all my muscle stiffness?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the primary goal of adjusting my spasticity medication right now—reducing pain, improving ease of care, or helping me walk?
- 2.How will we measure if the medication is causing too much weakness?
- 3.Have you noticed any 'buckling' of my knees or increased difficulty standing since we started or changed my anti-spasticity medication?
- 4.Would targeted Botox injections be a better option for my tightest muscles to avoid the full-body weakness caused by oral medications?
- 5.How frequently should we monitor my fall risk and balance as we adjust these medications?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (15)
- 1
Integrative Organelle-Based Functional Proteomics: In Silico Prediction of Impaired Functional Annotations in SACS KO Cell Model.
Morani F, Doccini S, Galatolo D, et al.
Biomolecules 2022; (12(8)) doi:10.3390/biom12081024.
PMID: 35892334 - 2
ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.
Salem IH, Blais M, Zuluaga-Sánchez VM, et al.
Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.
PMID: 39753868 - 3
GABAB Receptor Chemistry and Pharmacology: Agonists, Antagonists, and Allosteric Modulators.
Nieto A, Bailey T, Kaczanowska K, McDonald P
Current topics in behavioral neurosciences 2022; (52()):81-118 doi:10.1007/7854_2021_232.
PMID: 34036555 - 4
Cannabis use in patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.
Beauchesne W, Ouellet-Dupuis F, Frigon MA, et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; (103()):44-48 doi:10.1016/j.jocn.2022.06.019.
PMID: 35809457 - 5
Comprehensive pain management in spinal surgery: The role of botulinum toxin.
Batifol D, Finiels PJ, Galmiche S, de Boutray M
Neuro-Chirurgie 2025; (71(4)):101678 doi:10.1016/j.neuchi.2025.101678.
PMID: 40349915 - 6
Functional mobility in walking adult population with ataxia of Charlevoix-Saguenay.
Lessard I, St-Gelais R, Hébert LJ, et al.
Orphanet journal of rare diseases 2021; (16(1)):432 doi:10.1186/s13023-021-02054-2.
PMID: 34649570 - 7
Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life.
McCormick ZL, Chu SK, Binler D, et al.
PM & R : the journal of injury, function, and rehabilitation 2016; (8(6)):553-62.
PMID: 26498518 - 8
Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review.
Iqbal M, Modi P, Sehgal K, et al.
CNS drugs 2026; (40(3)):419-449 doi:10.1007/s40263-025-01254-9.
PMID: 41555041 - 9
Baclofen-induced neurotoxicity in a dialysis patient managed with continuous venovenous hemodialysis: A case report and literature review.
Ellouze NF, Hazra D, Al Abri S
Turkish journal of emergency medicine 2024; (24(3)):176-179 doi:10.4103/tjem.tjem_231_23.
PMID: 39108680 - 10
An Uncommon Side Effect of Baclofen Withdrawal in End Stage Renal Disease.
Sheth K, Odukoya D, Joseph K, Agarwal A
Cureus 2024; (16(5)):e60411 doi:10.7759/cureus.60411.
PMID: 38882970 - 11
Use of Baclofen as a Treatment for Nocturnal Calf Cramps in Individuals With Lumbar Spinal Stenosis: A Prospective Randomized Study.
Kim HJ, Yoon KB, Kang M, et al.
American journal of physical medicine & rehabilitation 2024; (103(5)):384-389 doi:10.1097/PHM.0000000000002364.
PMID: 38063320 - 12
Effect of Botulinum Toxin Injections in the Treatment of Spasticity of Different Etiologies: An Umbrella Review.
Otero-Luis I, Martinez-Rodrigo A, Cavero-Redondo I, et al.
Pharmaceuticals (Basel, Switzerland) 2024; (17(3)) doi:10.3390/ph17030310.
PMID: 38543096 - 13
Validity and reliability of the LEMOCOT in the adult ARSACS population: A measure of lower limb coordination.
Lessard I, Lavoie C, Côté I, et al.
Journal of the neurological sciences 2017; (377()):193-196 doi:10.1016/j.jns.2017.03.046.
PMID: 28477695 - 14
Efficacy of Manual Wheelchair Skills Training for Improving Skills and Confidence in People With Hereditary Degenerative Disorders: Protocol for a Sequential Multimethods Study.
Niyomwungere E, Routhier F, Gagnon C, et al.
JMIR research protocols 2025; (14()):e66974 doi:10.2196/66974.
PMID: 40742628 - 15
Development and validation of a disease severity index for ataxia of Charlevoix-Saguenay.
Gagnon C, Brais B, Lessard I, et al.
Neurology 2019; (93(16)):e1543-e1549 doi:10.1212/WNL.0000000000008313.
PMID: 31534027
This page provides information on managing ARSACS muscle spasticity for educational purposes only. Always consult your neurologist before starting or adjusting medications, as balancing muscle tone and weakness is critical for your safety and mobility.
Get notified when new evidence is published on Autosomal recessive spastic ataxia of Charlevoix-Saguenay.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.